The impact of herpes zoster and post-herpetic neuralgia on quality-of-life

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Johnson, Robert W ^a   Bouhassira, Didier ^b   Kassianos, George ^a   Leplège, Alain ^c   Schmader, Kenneth E ^d   Weinke, Thomas ^e  

^a APHP ^*  (United Kingdom)

^b HÔPITAL AMBROISE PARÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d DURHAM VA MEDICAL CENTER   (United States)

^e KLINIKUM ERNST VON BERGMANN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; ANTIVIRUS AGENT; CAPSAICIN; CORTICOSTEROID; FAMCICLOVIR; GABAPENTIN; LIDOCAINE; LOCAL ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT; PLACEBO; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ADL DISABILITY; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FUNCTIONAL STATUS; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HOSPITALIZATION; HUMAN; INCIDENCE; INJECTION SITE REACTION; PAIN ASSESSMENT; PATIENT SATISFACTION; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; PSYCHOLOGICAL ASPECT;

HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC; QUALITY OF LIFE;

EID: 77953681563     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-37     Document Type: Article

References (89)

1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007, 356:1338-1343. 10.1056/NEJMct066061, 17392303.
2. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20. 1898279, 14267505.
3. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005, 352:2266-2267. 10.1056/NEJMp058091, 15930416.
4. Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005, 6:317-325. 10.2165/00128071-200506050-00005, 16252931.
5. Gnann JW, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002, 347:340-346. 10.1056/NEJMcp013211, 12151472.
6. Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007, 11(Suppl 2):S43-S48. 10.1016/S1201-9712(07)60021-6, 18162246.
7. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996, 9:361-381. 172899, 8809466.
8. Schmader K, Gnann JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008, 197(Suppl 2):S207-S215. 10.1086/522152, 18419399.
9. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002, 19:471-475. 10.1093/fampra/19.5.471, 12356697.
10. Dworkin RH, Gnann JW, Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008, 9(Suppl 1):S37-S44. 10.1016/j.jpain.2007.10.008, 18166464.
11. Johnson RW. Zoster-associated pain: what is known, who is at risk and how can it be managed?. Herpes 2007, 14(Suppl 2):30A-34A.
12. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006, 145:317-325.
13. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005, 6:356-363. 10.1016/j.jpain.2005.01.359, 15943957.
14. Arvin AM. Varicella-zoster virus. Fields Virology 2001, 2:2731-2768. Philadelphia: Lippincott Williams & Wilkins, Knipe DM, Howley PM, 4.
15. Johnson RW. Herpes zoster and postherpetic neuralgia: a review of the effects of vaccination. Aging Clin Exp Res 2009, 21:236-243.
16. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137:38-47. 10.1017/S0950268808000678, 18466661.
17. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 2009, 27:520-529. 10.1016/j.vaccine.2008.11.012, 19027048.
18. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004, 39:342-348. 10.1086/421942, 15307000.
19. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5:344-356. 10.1016/j.jpain.2004.06.001, 15336639.
20. Volpi A. Severe complications of herpes zoster. Herpes 2007, 14(Suppl 2):35A-39A.
21. World Health Organization Constitution of the World Health Organization. Basic Documents. 2006, Geneva: WHO, 45, World Health Organization.
22. University of Toronto The Quality of Life Model. 2009, University of Toronto., http://www.utoronto.ca/qol/concepts.htm
23. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003, 106:337-345. 10.1016/j.pain.2003.08.001, 14659516.
24. Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999, 28:736-739. 10.1086/515205, 10825029.
25. Khanna D, Tsevat J. Health-related quality of life - an introduction. Am J Manag Care 2007, 13(Suppl 9):S218-S223.
26. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 2007, 23:490-496. 10.1097/AJP.0b013e318065b6c9, 17575488.
27. Norquist J, Nikas A, Saddier P, Choo P, Levin M, Oxman M, Schmader K. Measuring aspects of daily life in patients with herpes zoster. 2005, San Francisco, CA, USA, (Abstract). International Society for Quality of Life Research, 12th Annual Conference.
28. Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008, 25:991-1006. 10.2165/0002512-200825120-00002, 19021299.
29. Breuer J, Whitley R. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 2007, 14(Suppl 2):25-29. [Erratum in Herpes 2007, 14: 74].
30. Katz J, Melzack R. Measurement of pain. Surg Clin North Am 1999, 79:231-252. 10.1016/S0039-6109(05)70381-9, 10352653.
31. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med 1997, 157:1217-1224. 10.1001/archinte.157.11.1217, 9183233.
32. Whitley RJ, Shukla S, Crooks RJ. The identification of risk factors associated with persistent pain following herpes zoster. J Infect Dis 1998, 178(Suppl 1):S71-S75. 10.1086/514274, 9852979.
33. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004, 62:1545-1551.
34. Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008, 80:1646-1652. 10.1002/jmv.21254, 18649332.
35. Pavan-Langston D. Ophthalmic zoster. Varicella-Zoster Virus, Virology and Clinical Management 2000, 276-298. Cambridge Press, Arvin AM, Gershon AA.
36. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995, 45(Suppl 8):S52-S53.
37. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001, 32:1481-1486. 10.1086/320169, 11317250.
38. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, Hasnaoui A E, de Labareyre C. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001, 33:62-69. 10.1086/320884, 11389496.
39. Oaklander AL, Bowsher D, Galer B, Haanpää M, Jensen MP. Herpes zoster itch: preliminary epidemiologic data. J Pain 2003, 4:338-343. 10.1016/S1526-5900(03)00637-0, 14622691.
40. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-137. 10.1093/ageing/afj048, 16431855.
41. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-354. 10.1097/00002508-200211000-00002, 12441828.
42. Mauskopf J, Austin R, Dix L, Berzon R. The Nottingham Health Profile as a measure of quality of life in zoster patients: convergent and discriminant validity. Qual Life Res 1994, 3:431-435. 10.1007/BF00435395, 7866361.
43. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med 2007, 23:615-632. vii-viii, 10.1016/j.cger.2007.03.003, 17631237.
44. Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 2004, 5:551-559. 10.1517/14656566.5.3.551, 15013924.
45. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009, 40:3443-3448. 10.1161/STROKEAHA.109.562017, 19815828.
46. Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology 2010, 74:792-797. 10.1212/WNL.0b013e3181d31e5c, 20200348.
47. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341-1349. [Erratum in: Mayo Clin Proc 2008; 83: 255], 10.4065/82.11.1341, 17976353.
48. di Luzio Paparatti U, Arpinelli F, Visonà G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999, 38:116-120. 10.1016/S0163-4453(99)90079-8, 10342652.
49. Weinke T, Edte S, Schmitt S, Lukas K. Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey. J Public Health 2010,
50. Álvarez Pasquín MJ, Morató Agustí ML, San-Martín Rodríguez M, . y Grupo EPIZOSTER Impacto del herpes zóster con o sin neuralgia postherpética en la calidad de vida de los pacientes. 2008, Madrid, Spain, [Impact of HZ with or without PHN on patients' QoL]. Abstract. Congress Sociedad Española de Medicina de Familia y Comunitaria, Accessed 7 October 2009, y Grupo EPIZOSTER., http://congreso2008.semfyc.gatewaysc.com/archivos/file/Madrid202008/Post ers%20web%20final.pdf
51. Baanders AN, Heijmans MJ. The impact of chronic diseases: the partner's perspective. Fam Community Health 2007, 30:305-317.
52. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006, 24:1308-1314. 10.1016/j.vaccine.2005.09.026, 16352376.
53. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009, 27:1454-1467. 10.1016/j.vaccine.2008.12.024, 19135492.
54. de Melker H, Berbers G, Hahné S, Rümke H, van den Hof S, de Wit A, Boot H. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006, 24:3946-3952. 10.1016/j.vaccine.2006.02.017, 16564115.
55. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003, 70(Suppl 1):S9-S14. 10.1002/jmv.10313, 12627480.
56. Paul E, Thiel T. Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area. Hautarzt 1996, 47:604-609. [in German], 10.1007/s001050050476, 8964702.
57. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090. 10.1016/S0264-410X(01)00044-5, 11312002.
58. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000, 181:1897-1905. 10.1086/315492, 10837168.
59. McElhaney JE. Herpes zoster: a common disease that can have a devastating impact on patients' quality of life. Expert Rev Vaccines 2010, 9:27-30. 10.1586/erv.10.31, 20192715.
60. Dworkin RH. Post-herpetic neuralgia. Herpes 2006, 13(Suppl 1):21A-27A.
61. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30. [Erratum in MMWR Recomm Rep 2008; 57: 779].
62. Galluzzi KE. Management strategies for herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc 2007, 107(Suppl 1):S8-S13.
63. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996, 22:341-347.
64. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009, 2:CD006866.
65. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(Suppl 1):S1-26. 10.1086/510206, 17143845.
66. Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009, 63:1386-1391. 10.1111/j.1742-1241.2009.02089.x, 2779987, 19691624.
67. Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging 2007, 24:1-19. 10.2165/00002512-200724010-00001, 17233544.
68. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence-based proposal. Pain 2005, 118:289-305. 10.1016/j.pain.2005.08.013, 16213659.
69. Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008, 26:235-249. 10.2165/00019053-200826030-00006, 18282017.
70. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284. 10.1056/NEJMoa051016, 15930418.
71. Oxman MN, Levin MJ, . Shingles Prevention Study Group Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008, 197(Suppl 2):S228-S236. 10.1086/522159, 18419402, Shingles Prevention Study Group.
72. Schmader K, Saddier P, Johnson G, et al. The effect of a zoster vaccine on interference of herpes zoster with activities of daily living (ADL). 2006, Toronto, Canada, Abstract 859, 44th Annual Meeting of the Infectious Diseases Society of America.
73. Gnann JW. Vaccination to prevent herpes zoster in older adults. J Pain 2008, 9:S31-S36. 10.1016/j.jpain.2007.10.007, 18166463.
74. Liesegang TJ. Varicella-zoster virus eye disease. Cornea 1999, 18:511-531.
75. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005, 2:e164. 10.1371/journal.pmed.0020164, 1181872, 16013891.
76. Gnann JW. Antiviral therapy for herpes zoster. Herpes 2006, 13(Suppl 1):16A-20A.
77. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, Jones T, Rea T, Boon R, Saltzman R. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995, 123:89-96.
78. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995, 28:281-290. 10.1016/0166-3542(95)00066-6, 8669888.
79. Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Arch Neurol 2006, 63:940-942. 10.1001/archneur.63.7.noc60049, 16682531.
80. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994, 330:896-900. 10.1056/NEJM199403313301304, 8114860.
81. Whitley RJ, Gnann JW, Weiss HL, Soong SJ. Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res 1996, 29:67-68. 10.1016/0166-3542(95)00920-5, 8721549.
82. Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003, 60:1274-1283.
83. Sabatowski R, Gálvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004, 109:26-35. 10.1016/j.pain.2004.01.001, 15082123.
84. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998, 280:1837-1842. 10.1001/jama.280.21.1837, 9846778.
85. Pavan-Langston D. Herpes zoster antivirals and pain management. Ophthalmology 2008, 115(Suppl 2):S13-S20. 10.1016/j.ophtha.2007.10.012, 18243927.
86. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, Tobias J. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008, 7:1106-1112. NGX-4010 C116 Study Group [Erratum in Lancet Neurol 2009; 8: 31], 10.1016/S1474-4422(08)70228-X, 18977178.
87. Manabe H, Dan K, Hirata K, Hori K, Shono S, Tateshi S, Ishino H, Higa K. Optimum pain relief with continuous epidural infusion of local anesthetics shortens the duration of zoster-associated pain. Clin J Pain 2004, 20:302-308. 10.1097/00002508-200409000-00004, 15322436.
88. Pasqualucci A, Pasqualucci V, Galla F, De Angelis V, Marzocchi V, Colussi R, Paoletti F, Girardis M, Lugano M, Del Sindaco F. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol Scand 2000, 44:910-918. 10.1034/j.1399-6576.2000.440803.x, 10981565.
89. van Wijck AJ, Opstelten W, Moons KG, van Essen GA, Stolker RJ, Kalkman CJ, Verheij TJ. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006, 367:219-224. 10.1016/S0140-6736(06)68032-X, 16427490.